Daniel Ryweck - Silo Pharma Chief Officer
| SILO Stock | USD 0.86 0.05 5.49% |
Insider
Daniel Ryweck is Chief Officer of Silo Pharma
| Age | 59 |
| Phone | 718 400 9031 |
| Web | https://silopharma.com |
Silo Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2486) % which means that it has lost $0.2486 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4397) %, meaning that it created substantial loss on money invested by shareholders. Silo Pharma's management efficiency ratios could be used to measure how well Silo Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kerry MD | Terns Pharmaceuticals | N/A | |
| BS CMAR | Champions Oncology | N/A | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Jean Volatier | Inventiva Sa | 60 | |
| Ian McNiece | Biocardia | 70 | |
| Pierre Broqua | Inventiva Sa | 62 | |
| Steven Ruhl | Forte Biosciences | 67 | |
| Michael Newman | Indaptus Therapeutics | 68 | |
| Michael Diem | Century Therapeutics | 53 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Marine Popoff | Hookipa Pharma | N/A | |
| Frederic Cren | Inventiva Sa | 58 | |
| Maria Mancini | Champions Oncology | N/A | |
| Jason Smith | UroGen Pharma | 52 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| MS MBA | Inozyme Pharma | 47 | |
| Irena Konstantinova | Inventiva Sa | N/A | |
| Anne Moon | Tempest Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.25 |
Silo Pharma Management Team
Elected by the shareholders, the Silo Pharma's board of directors comprises two types of representatives: Silo Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Silo. The board's role is to monitor Silo Pharma's management team and ensure that shareholders' interests are well served. Silo Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Silo Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Vice Development | ||
| Eric Weisblum, President Chairman | ||
| Daniel Ryweck, Chief Officer |
Silo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Silo Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (53.47) % | ||||
| Current Valuation | (2.06 M) | ||||
| Shares Outstanding | 2.84 M | ||||
| Shares Owned By Insiders | 6.34 % | ||||
| Shares Owned By Institutions | 5.60 % | ||||
| Number Of Shares Shorted | 61.39 K | ||||
| Price To Earning | 118.39 X | ||||
| Price To Book | 0.93 X |
Pair Trading with Silo Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silo Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Silo OTC Stock
The ability to find closely correlated positions to Silo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silo Pharma to buy it.
The correlation of Silo Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Silo OTC Stock
Silo Pharma financial ratios help investors to determine whether Silo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Silo with respect to the benefits of owning Silo Pharma security.